ZIOPHARM Oncology

ZIOPHARM Oncology, Inc., is a biopharmaceutical company focused on the discovery and development of new cancer therapies. We are applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.
Company Growth (employees)
Type
Public
HQ
Boston, US
Size (employees)
36 (est)
ZIOPHARM Oncology is headquartered in Boston, US

Key People at ZIOPHARM Oncology

Jonathan Lewis

Jonathan Lewis

CEO
Caesar J. Belbel

Caesar J. Belbel

CLO

ZIOPHARM Oncology Office Locations

ZIOPHARM Oncology has an office in Boston

ZIOPHARM Oncology Data and Metrics

ZIOPHARM Oncology Financial Metrics

ZIOPHARM Oncology's revenue was reported to be $6.9 m in FY, 2016
USD

Net income (Q1, 2017)

(15.5 m)

EBIT (Q1, 2017)

(14 m)

Market capitalization (22-Aug-2017)

737.8 m

Cash (31-Mar-2017)

66.4 m
ZIOPHARM Oncology's current market capitalization is $737.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

800 k1.4 m4.3 m6.9 m

Revenue growth, %

72%216%58%

R&D expense

157.8 m

General and administrative expense

14.4 m

Operating expense total

172.2 m

EBIT

(356.9 m)(43.5 m)(120.1 m)(165.3 m)

EBIT margin, %

(44614%)(3168%)(2772%)(2409%)

Net Income

(340.8 m)(31.8 m)(120.1 m)(165.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

12 m

General and administrative expense

3 m2.8 m4.3 m7.1 m3.1 m3.8 m3.7 m3.5 m3.6 m

Operating expense total

3 m2.8 m4.3 m7.1 m3.1 m3.8 m3.7 m3.5 m15.6 m

EBIT

(11.2 m)(11.9 m)(78.2 m)(14.2 m)(18.2 m)(12 m)(131.2 m)(10.9 m)(14 m)

Net Income

(15.3 m)(21.4 m)(78.2 m)(92.4 m)(110.6 m)(12 m)(143.2 m)(154.1 m)(15.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

68.2 m42.8 m140.7 m81.1 m

Accounts Receivable

508.4 m

Inventories

1.9 m1.1 m11.4 m23.8 m

Current Assets

70.3 m44.1 m152.5 m104.9 m

PP&E

801 k531 k581 k843 k

Total Assets

71.8 m45.2 m153.7 m106.3 m

Accounts Payable

422 k2 m2 m156 k

Current Liabilities

7.8 m10.8 m18.1 m15.8 m

Total Liabilities

58.3 m

Retained Earnings

(372.6 m)(492.7 m)(658 m)

Total Equity

49.4 m33.8 m87.4 m(77.3 m)

Financial Leverage

1.5 x1.3 x1.8 x-1.4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

53 m46.1 m129.7 m118.6 m163.8 m124.8 m109 m94.7 m66.4 m

Current Assets

54 m47.8 m130.6 m123.1 m172.5 m140.4 m126.7 m115.7 m92.8 m

PP&E

683 k654 k426 k321 k262 k667 k682 k825 k1.1 m

Total Assets

55.3 m49.1 m131.6 m124 m173.4 m141.7 m128 m117.1 m94.5 m

Accounts Payable

447 k2 m779 k3.1 m4.2 m1.9 m2 m1.8 m226 k

Current Liabilities

10.8 m11.7 m10.5 m13.1 m29.6 m17.3 m16 m15.7 m17.5 m

Retained Earnings

(356.1 m)(362.2 m)(450.8 m)(465.1 m)(483.2 m)(504.7 m)(635.9 m)(646.8 m)(673.6 m)

Total Equity

37.7 m36.5 m120.6 m110.4 m93.8 m77.8 m(52 m)(64.4 m)(94.9 m)

Financial Leverage

1.5 x1.3 x1.1 x1.1 x1.8 x1.8 x-2.5 x-1.8 x-1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(57.1 m)(31.8 m)(120.1 m)(165.3 m)

Depreciation and Amortization

738 k462 k357 k290 k

Inventories

5 m809 k(10 m)(12 m)

Accounts Payable

(1.1 m)1.6 m4 k(1.9 m)

Cash From Operating Activities

(59.5 m)(36.7 m)(10 k)(58.3 m)

Purchases of PP&E

(132 k)(193 k)(412 k)(551 k)

Cash From Investing Activities

(131 k)(193 k)(412 k)(551 k)

Cash From Financing Activities

54.5 m11.4 m98.3 m(788 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(15.3 m)(21.4 m)(78.2 m)(92.4 m)(110.6 m)(12 m)(143.2 m)(154.1 m)(15.5 m)

Depreciation and Amortization

217 k339 k122 k236 k295 k72 k155 k227 k79 k

Accounts Payable

25 k1.5 m(1.2 m)1.1 m2.2 m(100 k)23 k(194 k)70 k

Cash From Operating Activities

(16.3 m)(26.8 m)(9.7 m)(21.4 m)23.8 m(16.1 m)(31.2 m)(45.3 m)(14.3 m)

Purchases of PP&E

(99 k)(193 k)(17 k)(22 k)(25 k)(157 k)(257 k)(469 k)(358 k)

Cash From Investing Activities

(99 k)(193 k)(17 k)(22 k)(25 k)(157 k)(257 k)(469 k)(358 k)

Cash From Financing Activities

1.2 m4.9 m96.6 m97.2 m97.3 m365 k(304 k)(304 k)29 k
Y, 2017

Financial Leverage

-1 x

ZIOPHARM Oncology Market Value History

Traffic Overview of ZIOPHARM Oncology

ZIOPHARM Oncology News and Updates

Here Are the Stocks You Can Trade on IEX’s New Stock Exchange

The exchange that inspired the book 'Flash Boys' opens for trading Friday.

ZIOPHARM Oncology Company Life and Culture

You may also be interested in